Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sawai Reports Slight Growth In Japan Amid Challenges

The Mild Increase Coincides With The Company’s Increased Focus On Its Domestic Market

Executive Summary

The company’s third quarter results come during its planned withdrawal from the US and the recent implementation of administrative dispositions in Japan on grounds of GMP violations.

You may also be interested in...



Down But Not Out: Nichi-Iko Hives Off Sagent, Exits North America

Seven years after it paid almost three quarters of a billion dollars for US-based Sagent, troubled Nichi-Iko is offloading the struggling business.

Is Sawai Heading For A Cash Creation Crisis?

Three quarters of the way through its financial year, Sawai has half as much cash on its balance sheet as it did at the same stage in 2021/22, as the Japanese firm continues to be dogged by lower government-mandated prices and higher costs at home.

Sawai Urges Japan To Take 'Best And Only Chance' To Reform Pricing Amid Generic Crisis

Kenzo Sawai, president of Japanese generics giant Sawai Pharmaceutical, tells Scrip in the first of a two-part exclusive interview about the firm’s strategy and backstory of efforts to maintain product supplies amid the country’s ongoing generic crisis. He also urges Japan to take "the best and only chance" to reform its drug pricing system to help the entire market survive.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153316

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel